Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Juli Miller – Investor Relations Adrian Rawcliffe – Chief Executive Officer Dennis Williams – Senior Vice President-Late Stage Development Elliot Norry – Chief Medical Officer Jo Brewer – Chief Scientific Officer Gavin Wood – Chief Financial Officer Conference Call Participants Jerry Gong – Mizuho Securities Marc Frahm – TD Cowen Dylan Drakes – Leerink Partners Yanan Zhu – Wells Fargo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or ot ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2023 Results Conference Call August 9, 2023 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Elliot Norry - Chief Medical Officer Gavin Wood - Chief Financial Officer Conference Call Participants Tony Butler - EF Hutton Marc Frahm - TD Cowen Jonathan Chang - Leerink Partners Mara Goldstein - Mizuho Operator Good morning, ladies and gentlemen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other j ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2023 Earnings Conference Call May 12, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Helen Tayton-Martin - Chief Business & Strategy Officer Joanna Brewer - Chief Scientific Officer John Lunger - Chief Patient Supply Officer Conference Call Participants Marc Frahm - TD Cowen Tony Butler - EF Hutton Operator Hello. Welcome to Adap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Garry Menzel - President and Chief Executive Officer, TCR2 Therapeutics Conference Call Participants Ernie Rodriguez - Cowen Mara Goldstein - Mizuho Tony Butler - EF Hutton Michael Schmidt - Guggenheim Jonathan Chang - SVB Securities Asthika Goonewardene - Truist Securities Kelly Shi - Jefferies Soumit Roy - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37368 ADAPTIMMUNE THERAPEUTICS PLC (Exact name of Registrant as specified in its charter) England and Wales Not Applicable (State or other juris ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Elliot Norry - Chief Medical Officer Gavin Wood - Chief Financial Officer Dennis Williams - Senior Vice President, Late Stage Development Jo Brewer - Chief Scientific Officer Helen Tayton-Martin - Chief Business and Strategy Officer Conference Call Participants Marc Frahm - Cowen & Company Tony Butler - R ...